IBJNews

People

January 14, 2013
Keywords
Back to TopE-mailPrintBookmark and Share

Jane Keller, CEO of the Indiana Orthopaedic Hospital and interim CEO of OrthoIndy, a large Indianapolis-based practice of orthopedic surgeons, has been named CEO of both companies. Keller took over as interim CEO of OrthoIndy in June 2012. Keller holds a nursing degree from Ball State University and an MBA from Butler University. She became chief nursing officer of the Indiana Orthopaedic Hospital in 2005 and was named CEO in 2006.

The Indianapolis-based Suburban Health Organization named Davis Lippincott as its new president, replacing Julie Carmichael, who recently left to become chief strategy officer at the St. Vincent Health hospital system. Lippincott previously was director of provider contracts and risk services for Suburban Health, a consortium of 10 hospital systems, including Indianapolis-based St. Vincent. Prior to joining Suburban Health, Lippincott worked as a financial analyst at Blue Cross and Blue Shield of Indiana and was an analyst and director of the care-management organization at St. Vincent Health. Lippincott holds a bachelor's degree from Purdue University and is a certified public accountant.
 

ADVERTISEMENT

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. So, Pence wants the federal government to ignore the 2008 law that allows children from these countries to argue for asylum in front of a judge. How did this guy become governor? And how is that we'll soon be subjected to repeatedly seeing him on TV being taken seriously as a presidential candidate? Am I in Bizzaro-U.S.A.?

  2. "And the most rigorous studies of one-year preschool programs have shown short-term benefits that fade out in a few years or no benefits at all." So we are going down a path that seems to have proven not to work very well. Right intention, wrong approach?

  3. Well for Dunkin Donuts it might say that even a highly popular outlet can't make a poorly sited location work. That little strip has seen near constant churn for years.

  4. Years ago, the Pharmaceutical and Medical Device companies shifted their research investment away from Medical Institutions to focus more on private research centers, primarily because of medical institution inefficiencies in initiating clinical studies and their inability/commitment to enroll the needed number of patients in these studies. The protracted timelines of the medical institutions were prompting significant delays in the availability of new drug and medical device entities for patients and relatedly, higher R and D expenditures to the commercial industry because of these delays. While the above stated IU Health "ratio is about $2.50 in federal funding for every $1 in industry funding", the available funding is REVERSED as commercial R and D (primarily Phase I-IV clinical work)runs $2.50 to $1 for available federal funding ($76.8B to $30.9B in 2011). The above article significatly understated the available R and D funding from industry......see the Pharma and Medical Device industry websites. Clearly, if medical institutions like IU Health wish to attract more commercial studies, they will need to become more competitive with private clinical sites in their ability to be more efficient and in their commitment to meet study enrollment goals on time. Lastly, to the reference to the above Washington Post article headlined “As drug industry’s influence over research grows, so does the potential for bias", lacks some credibility as both FDA and Institutional Institutional Review Boards must approve the high proportion of these studies before studies are started. This means that both study safety and science must be approved by both entities.

  5. ChIeF and all the other critics – better is better no matter what. Get over it; they are doing better despite you ?

ADVERTISEMENT